Michael Wang, MD, professor, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from the TRANSCEND-NHL-001 study, which was designed to investigate lisocabtagene maraleucel in patients with relapsed/refractory mantle cell lymphoma. The overall response was comparable to other therapies, with a reduction in toxicity. These results suggest that lisocabtagene maraleucel may be an alternative option for patients who cannot receive other CAR T-cell therapies.